Roche lands Tecentriq trial win, still trails Merck in lung cancer

“Roche Chief Medical Officer Sandra Horning said Roche’s data demonstrated Tecentriq was an effective treatment and might lead to additional treatment choices on offer for cancer victims” writes Midwest Communications Inc for ZURICH (Reuters) – Roche’s Tecentriq plus chemotherapy boosted lung cancer patients’ survival by nearly five months, study data released on Monday showed, underscoring benefits of the Swiss group’s immunotherapy but still leaving it trailing a rival’s drug.

Related posts